Noa Argamani has joined venture capital fund Vine Ventures, which invests in early-stage startups in artificial intelligence, cybersecurity, and defense technology. She aims to help Israeli founders expand into the U.S. market, viewing herself as a bridge between the two countries. After being rescued from captivity, Argamani pursued studies in AI and entrepreneurship before deciding that venture capital would allow her to make a greater impact than coding alone.
The FDA approved tavapadon (Juvmo), a new Parkinson's drug developed by AbbVie that takes a different approach by targeting D1 and D5 dopamine receptors instead of the D2 receptors used by existing treatments. Clinical trials showed the once-daily pill produced significant improvements in movement and daily functioning, with about 45-46% of patients reporting marked improvement compared to 12-19% on placebo. The drug was designed to avoid side effects of earlier D1-targeting compounds by being resistant to enzymatic breakdown and providing only partial receptor activation.